Trial Profile
Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapy in Subjects With Diffuse Cutaneous Systemic Sclerosis
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Terguride (Primary)
- Indications Sclerosis
- Focus Therapeutic Use
- Acronyms TERGISS
- Sponsors Medac
- 30 Jul 2020 This trial is discontinued in UK (Global End Date: 05 Jun 2018), according to European Clinical Trials Database record.
- 17 Jan 2020 Status changed to suspended.
- 14 Nov 2018 This trial has been Discontinued in Portugal (End date: 2018-06-05) as per European Clinical Trials Database record.